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The host response following malaria infection depends on a ﬁne balance between lev-
els of pro-inﬂammatory and anti-inﬂammatory mediators resulting in the resolution of the
infection or immune-mediated pathology. Whilst other components of the innate immune
system contribute to the pro-inﬂammatory milieu,T cells play a major role. For blood-stage
malaria, CD4+ and γδ T cells are major producers of the IFN-γ that controls parasitemia,
however, a role for TH17 cells secreting IL-17A and other cytokines, including IL-17F and
IL-22 has not yet been investigated in malaria.TH17 cells have been shown to play a role in
some protozoan infections, but they also are a source of pro-inﬂammatory cytokines known
to be involved in protection or pathogenicity of infections. In the present study, we have
investigated whether IL-17A and IL-22 are induced during a Plasmodium chabaudi infec-
tion in mice, and whether these cytokines contribute to either protection or to pathology
induced during the infection. Although small numbers of IL-17- and IL-22-producing CD4 T
cells are induced in the spleens of infected mice, a more pronounced induction is observed
in the liver, where increases in mRNA for IL-17A and, to a lesser extent, IL-22 were observed
and CD8+ T cells, rather than CD4 T cells, are a major source of these cytokines in this
organ. Although the lack of IL-17 did not affect the outcome of infection or pathology, lack
of IL-22 resulted in 50% mortality within 12 days after infection with signiﬁcantly greater
weight loss at the peak of infection and signiﬁcant increase in alanine transaminase in the
plasma in the acute infection. As parasitemias and temperature were similar in IL-22 KO and
wild-type control mice, our observations support the idea that IL-22 but not IL-17 provides
protection from the potentially lethal effects of liver damage during a primary P. chabaudi
infection.
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INTRODUCTION
The outcome of infection with the malaria parasite is determined
by factors affecting the tight balance in the kinetics and magnitude
of pro-inﬂammatory and anti-inﬂammatory cytokine produced
by the innate and acquired immune response (Langhorne et al.,
2008). In Plasmodium (P.) chabaudi infections in mice, TH1 CD4+
T cells play a dual role: mediating protective immunity, together
with B cells during blood-stage infection (Meding and Langhorne,
1991), and contributing to severe inﬂammation and pathogene-
sis through the production of IFN-γ (Li et al., 2003). However,
since the identiﬁcation of TH17 cells (Mangan et al., 2006; Veld-
hoen et al., 2006) and the discovery of the plasticity of T cell
cytokine responses (Zhou et al., 2009; O’Shea and Paul, 2010), the
TH1/TH2 paradigm in infections has been revisited, and protec-
tion or immunopathology has also been attributed to other cells
types such as TH17 cells in some infection models (Awasthi and
Abbreviations:AHR,aryl hydrocarbon receptor;ALT,alanine transaminase; IMDM,
Iscove’s medium; i.p., intraperitoneally; iRBC, infected red blood cells; KO,
knockout; P., Plasmodium; qRT-PCR, quantitative real-time PCR; WT, wild-type.
Kuchroo, 2009). Although the involvement of pro-inﬂammatory
cytokines derived from CD4+ TH1 cells in either immunopathol-
ogy or immunity to malaria has been extensively investigated, any
role of the cytokines IL-17 and IL-22 produced by TH17 cells or
other cells remains undetermined in P. chabaudi infections. In
addition, since TH17 cells themselves have a considerable plas-
ticity, they could also be a potential source of IFN-γ (Kurschus
et al., 2010), which hitherto was thought to be produced mainly
by CD4+ TH1 cells in malaria infections.
TH17 cells are identiﬁed and distinguished by their ability to
secrete IL-17A and other cytokines, including IL-17F and IL-
22. They can coordinate local tissue inﬂammation through the
up-regulation of pro-inﬂammatory cytokines and chemokines
including IL-6, IL-8, G-CSF, and MCP-1, recruiting neutrophils
and activating T cells (Aggarwal et al., 2003; Moseley et al., 2003).
Moreover, TH17 cells were shown to have the ability to produce
both IFN-γ and IL-17, or, in vitro, to shut off IL-17 production
(Annunziato et al., 2007; Bending et al., 2009; Lee et al., 2009;
Hirota et al., 2011). Although IL-17A was shown at ﬁrst to play a
major role in the pathogenesis of various autoimmune diseases in
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mousemodels (Langrish et al., 2005; Ivanov et al., 2006;Komiyama
et al., 2006; Steinman, 2007) induction of TH17 cells has also been
described in infections of Toxoplasma gondii (Kelly et al., 2005)
and Leishmania (Pitta et al., 2009), suggesting that they may play
a role in protection or immunopathology of parasitic diseases.
IL-22 is regulated by IL-23, differently from IL-17, and can
be co-expressed with IL-17A in TH17 cells (Liang et al., 2006;
Zheng et al., 2007). Its production by TH17 cells is dependent
on Notch signaling and the stimulation of the aryl hydrocarbon
receptor (AHR; Veldhoen et al., 2008; Alam et al., 2010). In fact,
the induction of c-Maf, downstream of TFG-β, has been demon-
strated as inducing suppression of IL-22 production in TH17 cells
(Rutz et al., 2011). IL-22 is also produced by NKT cells (Goto et al.,
2009),TH1, innate lymphoid cells (Taube et al., 2011), andNK cells
(Ren et al., 2011). IL-22 production is increased during chronic
inﬂammatory diseases. For example, it has been linked to tuber-
culosis (Matthews et al., 2011), and dermal inﬂammation such as
psoriasis, where it induces production of antimicrobial proteins
needed for the defense against pathogens in the skin (Wolk et al.,
2004; Sonnenberg et al., 2011) and gut (Aujla et al., 2008). IL-
22 also plays a protective role in hepatitis (Radaeva et al., 2004;
Xu et al., 2011; Zhang et al., 2011). Therefore, depending on the
tissues, TH17-derived IL-22 might either enhance inﬂammation
or limit the tissue damage induced by IL-17A (Wolk and Sabat,
2006; Zenewicz et al., 2007). There have been very few studies
investigating IL-17 or IL-22 in malaria, although one study in
West Africa identiﬁed polymorphisms in the IL-22 gene which are
associated with resistance and susceptibility (Koch et al., 2005)
suggesting a potential involvement of IL-22, and a second study
in macaque malaria/AIDS-virus co-infection model, has demon-
strated a protective role for IL-17 and IL-22, via TH1 response
inhibition (Ryan-Payseur et al., 2011). In the present study we
have investigated whether IL-17A and/or IL-22 are induced dur-
ing a P. chabaudi infection in mice, and whether these cytokines
contribute to either protection or to pathology induced during
the infection. We show that IL-22 but not IL-17 provides protec-
tion from fatal liver tissue damage during a primary P. chabaudi
infection.
MATERIALS AND METHODS
MICE, PARASITES, AND INFECTION
All experimental animals were kept in pathogen-free animal
facilities at the MRC National Institute for Medical Research
(NIMR, London, UK) in accordance with local guidelines.
Male and female C57BL/6 mice, Il17aCre+/+R26ReYFP mice and
Il17aCre+/−R26ReYFP mice (Hirota et al., 2011), il17A−/− mice,
kindly provided by Dr. A. Smith (Schmidt and Bradﬁeld, 1996),
and il22−/− mice (Kreymborg et al., 2007). All knockout (KO)
mice were bred in the NIMR speciﬁc pathogen-free unit on the
C57BL/6 background and the genotype of each of the mice was
always veriﬁed before use. All mice were used at 6–8weeks of age.
The Il17aCre+/+R26ReYFP mice and Il17aCre+/−R26ReYFP mice
allow permanent tracing of cells with activation of the locus
encoding the signature cytokine IL-17A. Brieﬂy, the Cre recom-
binase activity is visualized by eYFP expression from the Rosa26
promoter. Therefore, eYFP is expressed in all cells that had acti-
vated IL-17A and their progeny, thus allowing the identiﬁcation
of cells that have switched on the IL-17 program as well as
alternative effector programs that might have been activated.
In the Il17aCre+/+R26ReYFP mice (Cre/Cre homozygous), the
IL-17A gene is replaced by the Cre recombinase, whereas in
Il17aCre+/−R26ReYFP mice (Cre± heterozygous), IL-17A is not
replaced by theCre recombinase, allowing tracking of IL-17AeYFP+
expression in vivo.
Mice were infected with 1× 105 P. chabaudi (AS) infected red
blood cells (iRBC) and parasitemia, weight loss, and body temper-
ature were monitored as previously described (Li et al., 2003). All
animal experiments were conducted under a British Home Ofﬁce
license and according to international guidelines and UK Home
Ofﬁce regulations, after approval from the NIMR Ethical Review
Panel.
CELL LINES AND PEPTIDES
Monoclonal antibodies speciﬁc for IL-17A [Uyttenhove and Van
Snick, 2006; clone MM17F3, mouse Immunoglobulin G (IgG) 1]
and IL-22 (Ma et al., 2008;Dumoutier et al., 2009;AM 22.1,mouse
IgG2a) were used for in vivo neutralization and for ﬂow cytom-
etry. The hybridomas were cultured in Iscove’s medium (IMDM,
Sigma, UK) with 5% fetal calf serum (FCS), 1mM l-Glutamine,
10mM Hepes, 5× 10−5 M β-Mercaptoethanol, 100 μg/ml peni-
cillin, 100U/ml streptomycin, and 1mM Sodium pyruvate (com-
plete IMDM), and puriﬁed from in vitro cultures by Pro-
tein A (Bio-Rad) afﬁnity chromatography (Endotoxin <10 IU).
0.5mg/mouse of neutralizing antibodywas given intraperitoneally
(i.p.), twice weekly or every other day for anti-IL-17A and
anti-IL-22 treatment, respectively.
ANTIBODIES AND FLOW CYTOMETRIC ANALYSIS
Spleen cells from naïve or P. chabaudi-infected mice were mashed
through a 70-μm sieve (Falcon) into complete IMDM to create
a single-cell suspension. Erythrocytes were lysed with red blood
cell lysis buffer (Sigma), and the cell pellet was washed and resus-
pended in FACS buffer [1% (wt/vol) bovine serum albumin, 5mM
EDTA, and 0.01% sodium azide in PBS]. Mononuclear liver cells
were isolated as described inTupin andKronenberg (2006). Brieﬂy,
the liver is perfused with PBS to remove external blood and placed
into 5ml IMDM+ 2% FCS+ 10mM HEPES. The whole liver is
mashed through a 70-μm ﬁlter to give a single-cell suspension,
and centrifuged at RT for 7min at 500 g. The cell pellet is washed
with 10ml IMDM+ 2% FCS+ 10mM HEPES and centrifuged
as before. The cell pellet is resuspended in 25ml of 37.5% Per-
coll+ 100U/ml Heparin in IMDM (at RT), and centrifuged at RT
for 12min at 700 g with no brake. The mononuclear cells form
a tight pellet at the base of the tube. The supernatant is removed
and the cell pellet resuspended in IMDM, and centrifuged at 4˚C
for 5min at 300 g.
Antibodies used were CD8α Biotin, CD4 Paciﬁc Blue, TCRγδ
PE, NK1.1 PE, IL-17A Alexa Fluor 647, and IFN-γ FITC (eBio-
sciences, Insight Biotechnology, London, UK). IL-22 was detected
using the polyclonal PE anti-mouse IL-22 antibody (BioLegend).
Isotype controls were included in each staining. Before addition
of speciﬁc ﬂuorescently labeled antibodies, 2× 106 cells were pre-
incubated at room temperature for 10min with anti-Fc receptor
antibody (Unkeless, 1979) to prevent non-speciﬁc binding via the
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FcR. All other preparations with antibodies for extracellular stain-
ing were incubated for 20min on ice. For intracellular staining,
cells were stimulated with 50 ng/ml PMA (Sigma), 500 ng/ml Ion-
omycin (Sigma) for 2 h at 37˚C, 7% CO2. Ten micrograms per
milliliter Brefeldin A (Sigma) was added for the last 2 h of cul-
ture. In Figure 3, cells were restimulated with 500 ng/ml Phorbol
dibutyrate (PdBU) and 500 ng/ml ionomycin in the presence of
1μg/ml Brefeldin A (Sigma) for 2 h. Cells were then ﬁxed with
3.65% formaldehyde solution from Sigma and permeabilized with
0.1% NP40 before intracellular staining. Data were acquired on a
CyAn ADP analyzer (Beckman Coulter Cyan ADP) using Sum-
mit software, and the proportions of cells were determined using
FlowJo software (Treestar).
RNA EXTRACTION AND cDNA SYNTHESIS
Total RNA was extracted from 5× 106 cells splenocytes or
mononuclear cells from liver from uninfected and P. chabaudi-
infected mice. Cells were resuspended in TRIzol reagent (Life
Technologies), according to the manufacturer’s instructions, after
which 5μg of total RNA were reverse transcribed using Super-
script II RT (Life Technologies) at 42˚C for 50min, 70˚C 15min,
in the presence of 50mM Tris–HCl pH 8.3, 75mM KCl, 3mM
MgCl2, 5mM DTT (Dithiothreitol), 0.5mM dNTPs, 8U RNasin,
and 5μM Oligo(dT)16. The cDNA was ﬁnally treated with 2.5U
RNAse H at 37˚C for 20min to remove any RNA residues.
QUANTITATIVE REAL-TIME PCR
Real-time quantitative PCR reactions were performed using SYBR
Green PCR Core Reagents (ABgene). PCR ampliﬁcations were
performed in duplicate wells in a total volume of 25 μl, contain-
ing 1μl cDNA sample, 2μM of each primer, 12.5ml of Absolute
QPCR SYBR green mix, according to the manufacturer’s instruc-
tions. The resultant PCR products were measured and elaborated
using an Applied Biosystems GenApm 7000 Sequence detec-
tion system (ABI Prism 7000; primers sequences, Table A1 in
Appendix).
The PCR cycling protocol entailed 1 cycle at 50˚C for 2min and
then 95˚C for 15min, to activate the DNA polymerase, followed
by 40 cycles each consisting of 95˚C for 15 s and 1min at 60˚C.
Analysis of the relative changes (arbitrary units) in gene expres-
sion required calculations based on the cycle threshold (CT) fol-
lowing the 2−ΔΔCT method (Pfafﬂ, 2001). ΔΔCT was calculated
as the difference between the ΔCT values of the samples and the
ΔCTvalues of a calibrator sample; 2−ΔΔCT was the relativemRNA
unit representing the fold induction over control.
All quantiﬁcations were normalized to the level of Ubiquitin
gene expression (housekeeping gene). Test samples were expressed
as the fold increase of gene expression compared with expres-
sion in normal uninfected mice (mean of expression from three
uninfected mice).
PLASMA CYTOKINE MEASUREMENTS
Cytokine production was measured in the supernatant with a
bead-based (Multiplex) cytokine detection assay (eBioscience,
UK). The samples were processed using the manufacturers pro-
tocol and acquired on FACS Calibur and analyzed using FlowCy-
tomix™Pro 2.4 software (eBiosciences).
ALANINE TRANSAMINASE QUANTITATION IN PLASMA
Mouse blood samples were collected and centrifuged for collec-
tion of plasma. Plasma samples from naïve and infected samples
were diluted 1:10 or 1:100, respectively in PBS. Levels of alanine
transaminases (ALT) in serumwere quantiﬁed using a Cobas C111
chemistry analyzer (Roche).
STATISTICAL ANALYSIS
Data are shownasmeans andSEM,and signiﬁcant differenceswere
analyzed using a non-parametric Mann–Whitney U -test, p< 0.05
was accepted as statistically signiﬁcant difference.
RESULTS
TH17 CELLS SIGNATURE CYTOKINES, IL-17A AND IL-17F, mRNA
TRANSCRIPTS ARE INCREASED IN THE LIVER DURING A PRIMARY P.
CHABAUDI INFECTION
Plasmodium chabaudi blood-stage infections in mice are charac-
terized by an acute inﬂammatory response with the induction
of TNF-α, IL-1, IL-6, and IFN-γ within the ﬁrst 10–15 days of
infection, all of which could contribute to the pathology accom-
panying this stage of the infection. In order to determine whether
TH17 cells could play any role in controlling parasitemia and/or
immunopathologywe ﬁrst analyzed by quantitative real-time PCR
(qRT-PCR) whether mRNAs for the TH17 signature cytokines IL-
17A, IL-17F, and IL-22were induced in lymphocytes andmononu-
clear cells in spleen and liver, respectively, during a P. chabaudi
infection (Figure 1A).
In direct contrast to the well-described increase in IFN-γ tran-
scription in spleens (Stevenson et al., 1990; vonderWeid andLang-
horne, 1993) during the ﬁrst 7–11 days of infection (Figure 1B),
IL-17A mRNA levels were elevated within 1–2 days after infec-
tion but then markedly decreased over time (Figure 1B), to the
levels found in naive mice, particularly at peak parasitemia (days
7–11), suggesting that the spleen environment during P. chabaudi
infection, rich in IFN-γ mRNA expression, may negatively reg-
ulate IL-17 expression. However, IL-17F mRNA levels were not
substantially altered by the infection (±0.5-fold change relative to
naïve controls).
A markedly different response of IL-17A and IL-17F was
observed in the liver, which also enlarges during malaria (Dockrell
et al., 1980), coincidentwith an increase in IFN-γ expression, large,
and transient increases in IL-17A and IL-17F mRNA transcripts
compared with naïve controls (200- and 50-fold, respectively)
were detected at day 7 post-infection (Figure 1C). Similarly to
the results observed in the spleen (Figure 1B), IL-22 mRNA was
detectable in the liver early in the infection, but at low levels (an
approximately 1.4-fold increase compared with naïve controls,
Figure 1C).
Therefore, P. chabaudi infection induced a down-regulation
of IL-17 expression in the spleen, whereas, in the liver, infection
induced increased IL-17 mRNA expression, indicating a potential
role for IL-17 during a blood-stage P. chabaudi infection.
IN VIVO KINETICS OF IL-17A AND IL-22 EXPRESSION IN THE SPLEEN
AND LIVER OF MICE INFECTED WITH P. CHABAUDI
To assess whether IL-17 protein levels were consistent with the
mRNA transcripts,we evaluated the kinetics of IL-17AeYFP expres-
sion in several T cell populations in IL-17-fate reporter mice
www.frontiersin.org April 2012 | Volume 3 | Article 85 | 3
Mastelic et al. IL-22 protects against malaria infection
FIGURE 1 |TH17 cells signature cytokines, IL-17A and IL-17F, mRNA
transcripts are increased in the liver during a primary P. chabaudi
infection. C57BL/6 mice were infected with 105 P. chabaudi and sacriﬁced
post-infection at the time points indicated. Spleen and liver mononuclear
cells were harvested from naïve and infected mice and analyzed by
real-time PCR. (A) Representative course of infection in C57BL/6 mice.
IFN-γ, IL-17A, IL-17F, and IL-22 mRNA levels were determined in naïve and
infected splenocytes (B) and liver mononuclear cells (C). Data are
normalized to Ubiquitin expression. Test samples were expressed as the
fold increase of gene expression compared with expression in normal
uninfected mice (mean of expression from three uninfected mice were set
at one) versus infected mice samples. Negative values represent levels of
gene expression lower than those measured in naïve mice. Data are
representative of two experiments and are obtained in groups of ﬁve mice
per time points (mean±SEM).
(Il17aCreR26ReYFP) infected with P. chabaudi (representative ﬂow
cytometry plots and gating strategies in Figure 2). Since the EYFP
IL-17 reporter mice report any cell that has ever expressed IL-17A,
it may not represent the cytokine status of the cells at the time
of sampling. Therefore, we also evaluated IL-17A expression by
intracellular staining in wild-type (WT) C57BL/6 mice infected
with P. chabaudi for the same times post-infection (Figures 2 and
3). Although IL-17A transcripts were low in splenocytes through-
out the course of infection, lymphocytes and mononuclear cells
expressing EYFP were readily detectable and their numbers signif-
icantly increased over time in both spleen and liver (Figure 3A). By
contrast, an increase in IL-17A expression by intracellular stain-
ing was only detected in liver mononuclear cells (Figure 3A),
correlating with the increased IL-17 mRNA detected in the liver.
As the EYFP fate reporter marks cells that are no longer neces-
sarily actively producing IL-17 at the times measured, there were
many more IL-17+ cells in the infected reporter mice than in the
C57BL/6 mice. However in both infected IL-17 reporter mice and
WT C57Bl/6 mice, CD4+ and CD8+ T cells were the predominant
sources of this cytokine in spleen and liver, respectively (shown for
days 5 and 7, Figure 3A).
Although both IL-17A+ and IFN-γ+ T cells were increased
in livers of the fate reporter mice following infection, very
few IL-17+IFN-γ+ double-producers were detected (Figure 3B).
Therefore, although a different experimental system previously
described a potential for TH17 cells to partially lose IL-17 expres-
sion and up-regulate IFN-γ (Kurschus et al., 2010), this does not
appear to be the case in this malaria infection and it is thus very
unlikely that any of the IFN-γ produced during malaria infection
are derived from cells previously producing IL-17.
Althoughwe couldnot detect high levels of IL-22mRNAduring
P. chabaudi infection in either spleen or liver, they were elevated
compared with controls. As IL-22 has been reported to play a crit-
ical role during acute liver inﬂammation (Radaeva et al., 2004;
Zenewicz et al., 2007; Xu et al., 2011), we therefore investigated
IL-22 production by intracellular staining of lymphocyte pop-
ulations in the liver and spleen of infected C57BL/6 mice and
found increased numbers of IL-22-producing cells in both organs
(Figure 4A). Similar to IL-17A production, the predominant cells
producing IL-22 were CD4+ T cells in the spleen and CD8+ T cells
in the liver (Figures 4B,C). In agreement with a previous report
showing that NKT cells are important producers of the hepato-
protective cytokine IL-22 in mouse model of hepatitis (Wahl et al.,
2009), we observed that NKT cells were also signiﬁcant contribu-
tors to the production of IL-22 at day 5 of the P. chabaudi infection
(Figure 4A), although they represented only a very small fraction
of cells present in the liver (Figure 2C). However, no IL-22+/IL-
17+ or IL-22+/IFN-γ+ double-producers could be detected in
either the spleen or liver (Figure 4B,C), suggesting that either dis-
tinct kinetics and/or different sub-populations of CD8+ T cells
produce these cytokines.
LACK OF IL-22 BUT NOT IL-17A RESULTS IN INCREASED MORTALITY
AND LIVER DAMAGE DURING A P. CHABAUDI INFECTION
Despite the increased production of IL-17A and the greater num-
ber of T cells in the liver producing IL-17A during a P. chabaudi
infection, lack of IL-17A in either the Il17aCre+/+R26ReYFP mice,
or conventional Il17A−/− mice had little or no effect on para-
sitemia,weight loss,or hypothermia,when comparedwith infected
control Il17aCre+/−R26ReYFP mice which express IL-17, or control
C57BL/6 mice (Figure 5). Similarly, administration of neutraliz-
ing anti-IL-17A antibodies in control C57BL/6 mice did not alter
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FIGURE 2 | Gating strategies for IL-17 producing cells. IL-17-fate reporter
(Il17aCreR26ReYFP) and C57BL/6 mice were infected with 105 P. chabaudi and
sacriﬁced at days 3, 5, and 7 post-infection. (A) Representative ﬂow
cytometry plots of live cells gating in spleen and liver mononuclear cells. (B)
Gating strategy for CD3+, CD4+, CD8+, NK+, and γδ+ T cells, and CD3−NK+
cells. (C)Total cell numbers of the several T cells populations in C57BL/6
splenocytes and liver mononuclear cells during the ﬁrst 7 days of P. chabaudi
infection. (D) Representative ﬂow cytometry plots of IL-17EYFP or IL-17A+ cells
in CD4+ and CD8+ T cells of infected splenocytes and liver mononuclear cells
of reporter and C57BL/6 mice, respectively.
the course of the infection or any of the pathological parameters
tested compared with mice receiving isotype control antibodies
(data not shown).
In stark contrast, lack of IL-22 in IL-22 KO mice resulted in
50% mortality within 12 days after injection of 105 P. chabaudi
iRBC with signiﬁcantly greater weight loss at the peak of infec-
tion (Figure 6A). Although IL-22 KO mice had some difﬁ-
culty in controlling the infection with delayed clearance and
increased loss of body weight compared to controls, fulmi-
nant or increased parasitemia or extreme loss of body tem-
perature was not responsible for mortality as parasitemias and
temperature were similar in IL-22 KO (irrespective of whether
or not mice died) and WT control mice (Figure 6A). There was
no mortality in mice given with anti-IL-22 antibodies, and sim-
ilarly to the IL-22 KO mice there was no difference in weight
loss.
Experimental malaria infections in mice, including P. chabaudi
infections have been shown to cause liver pathology (Mota et al.,
2000; Kochar et al., 2003). As there was an increase in CD8+ and
NKT cells producing IL-22 and IL-17 inﬁltrating the liver during
the acute P. chabaudi infection (Figures 3 and 4), it was pos-
sible that in the absence of IL-22 there is an increase in liver
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FIGURE 3 | In vivo kinetics of IL-17A in spleen and liver of mice infected
with P. chabaudi. IL-17-fate reporter (Il17aCreR26ReYFP) and C57BL/6 mice
were infected with 105 P. chabaudi and sacrificed at days 3, 5, and 7
post-infection. (A)Total numbers of IL-17AeYFP- and IL-17+-cells (detected by
intracellular staining) in splenocytes and hepatocytes from naïve and infected
IL-17-fate reporter mice (left panel) and C57BL/6 mice (right panel),
respectively. The numbers represent the median and range of three mice. The
fraction of CD4+, CD8+, γδ+, NKT cells, and NK cells contributing to IL-17A+
production in spleen and liver at day 7 and 5, respectively. (B) Representative
ﬂow cytometry plots of IL-17AeYFP versus IFN-γ expression in CD4+ and CD8+
T cells, in liver cells, and splenocytes of naïve and day 5 and 7 infected mice.
Numbers in quadrants refer to the percentages of cells in each quadrant. Data
are representative of two experiments and are obtained in groups of three
mice per time points (mean±SEM).
damage. We therefore measured the amount of ALT in plasma
of P. chabaudi-infected IL-17- (Figure 5) and IL-22-deﬁcient
mice (Figures 6A,B), as an indicator of hepatocyte dysfunction
(Astegiano et al., 2004).
There was a trend towards lower plasmaALT in Il17aCre+/−R26
ReYFP and IL-17 KO mice compared with their WT controls dur-
ing the acute phase of the P. chabaudi infection, however these
differences were not signiﬁcant, suggesting that IL-17 does not
contribute in amajorway to liver pathology or to its control during
P. chabaudi infection (Figure 5).
Plasmodium chabaudi-infected IL-22 KO mice, in con-
trast, displayed a signiﬁcant increase in ALT in the plasma
in the acute infection (Figure 6A). Similarly, although there
was no increase in mortality, mice given neutralizing anti-
IL-22 Abs also exhibited signiﬁcantly greater ALT levels
compared with isotype control-treated and untreated mice
(Figure 6B).
We have previously shown that inactivation of regulatory
cytokines such as IL-10 results in increased pathology with a
proportion of mice suffering a lethal infection, caused by increased
production of pro-inﬂammatory cytokines such as TNF-α and
IFN-γ (Li et al., 1999). However, unlike an infection in IL-10 KO
mice there was no difference in the amounts of TNF-α, IFN-γ, or
IL-1β in infected IL-22KOmiceduring theﬁrst 10 days of infection
compared with WT mice suggesting that an enhanced inﬂam-
matory response was not the most likely cause of the mortality
observed (Figure 6C).
Together these data support the idea that IL-22 may be impor-
tant in controlling liver damage as a result of a P. chabaudi
infection, and can protect mice from its potentially lethal effects.
DISCUSSION
In the present study, we have demonstrated that IL-17- and IL-
22-producing CD8+ T cells are present and increase in number
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FIGURE 4 | In vivo kinetics of IL-22 in spleen and liver of mice
infected with P. chabaudi. C57BL/6 mice were infected with 105
P. chabaudi and sacrificed at days 3, 5, and 7 post-infection. (A)Total
numbers of IL-22+ cells in splenocytes and hepatocytes from naïve and
infected C57BL/6 mice. The fraction of CD4+, CD8+, γδ+, NKT cells, and
NK cells contributing to IL-22 production in infected splenocytes and
mononuclear liver cells on days 5 and 7 post-infection. The numbers
represent the median and range of four mice. Representative ﬂow
cytometry plots of IL-22 versus IL-17A (left panels) and IL-22 versus IFN-γ
(right panels) and expression in CD4+, and CD8+ T in naïve, day 5 and 7
infected liver mononuclear cells (B) and splenocytes (C). Numbers in
quadrants refer to the percentages of cells in each quadrant. Data are
representative of two experiments and are from groups of four mice per
time point.
in the liver of C57BL/6 mice during an acute blood-stage infec-
tion with P. chabaudi. Importantly, IL-22 produced during a
primary infection with the blood-stages of P. chabaudi plays
vital role in controlling liver damage during a primary infec-
tion, since in its absence there is an increase in plasma ALT,
and more than 50% of mice die during the ﬁrst 12 days of
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FIGURE 5 | Parasitemia and pathology in IL-17-fate reporter and IL-17 KO
mice. (A) Il17aCre+/+R26ReYFP and conventional (B) Il17A−/− mice were infected
with 105 P. chabaudi, ﬁve mice per group. The heterozygous reporter mice in
(A) also act as a control for the homozygous mice as the IL-17 gene is not
deleted in these mice. WT C57BL/6 mice were used as controls in (A,B).
Weight loss and hypothermia (pathology) were monitored daily. Parasitemias
are presented as percentage of parasitized RBC, and the error bars
represents the SEMs. Tail blood was collected to measure ALT variation
during the infection, using a colorimetric end-point method (adapted from
Reitman and Frankel, 1957). Brieﬂy, 20μl of test serum was added to 100μl
of the ALT substrate and incubated for 30min at 37˚C. Hundred microliters of
2,4-dinitrophenylhydrazine was then added and incubated a further 20min at
RT. One milliliter of 0.4M NaOH was added to stop the reaction and the OD
determined at 490 nm. Water was used as blank. OD values were then
converted into the equivalent enzyme units (U/ml) using a standard curve
derived from known concentrations of a pyruvate standard. The standard
curve for ALT was performed using pyruvate standards. Data are means and
SEM of ﬁve mice and representative of two experiments. Signiﬁcant
differences are shown using a Mann–Whitney U -test of ﬁve mice [*signiﬁcant
P -value (0.01–0.05)].
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FIGURE 6 | Lack of IL-22 but not IL-17A results in increased mortality and
liver damage during a P. chabaudi infection. C57BL/6 mice were treated
with either 0.5mg of anti-IL-22 antibody or an isotype control, every other day,
from day 0 to 14 post-infection. IL-22 KO mice and anti-IL-22 treated C57BL/6
mice were infected at day 0 with 105 P. chabaudi, ﬁve mice per group. Weight
loss and hypothermia were monitored daily. Parasitemias are presented as
percentage of parasitized RBC, and the error bars represents the SEMs. Tail
blood was collected to measure ALT variation during the infection, using a
Cobas C111 chemistry analyzer. Data are means and SEM of ﬁve mice and
representative of two experiments. Signiﬁcant differences are shown using a
Mann–Whitney U -test of ﬁve mice [*signiﬁcant P -value (0.01–0.05), **very
signiﬁcant P -value (0.001–0.01)]. (A) Survival, parasitemia, pathology, and liver
damage in IL-22 KO and WT mice. (B) Parasitemia and ALT levels in anti-IL-22
treated or control mice. (C) Plasma IL-1β, TNF-α, and IFN-γ levels were
determined by ELISA in naïve and day 7 and 9 infected IL-22 KO mice and WT
mice. The numbers and the median are represented of four mice.
infection. By contrast, although IL-17A is also produced early
during a P. chabaudi infection in the liver, largely by CD8+ T
cells, IL-17A-deﬁcient mice show little difference in liver dam-
age, parasitemia, or any other indicators of pathology compared
with infected control mice. Despite previous demonstrations of
plasticity of TH17 cells, which can develop into disease-causing
TH1 cells in autoimmune experimental allergic encephalitis (EAE)
and Type I Diabetes (Bending et al., 2009; Kurschus et al.,
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2010), we could ﬁnd no evidence in this malaria infection that
IFN-γ-producing CD4+ T cells had arisen from previous TH17
cells.
There is very little information on IL-22 in malaria, and no
direct evidence until now that IL-22 itself had any protective effect
in this infection. A large case–control study of severe malaria
in a West African population identiﬁed several weak associa-
tions with individual single-nucleotide polymorphisms in the Il22
gene, and deﬁned two IL-22 haplotypes associated with resis-
tance (IL22 − 1394A and IL22+ 708T alleles) or susceptibility
(IL22 − 1394G and the IL22+ 708C alleles; Koch et al., 2005). No
data are as yet available of the effects of these polymorphisms
on expression or regulation of IL-22. A recent study employ-
ing macaque models of co-infection with malaria and SHIV has
demonstrated that the expansion of TH17/TH22 cells attenuated
malaria and avoided fatal-virus-associated malaria by inhibit-
ing TH1 responses (Ryan-Payseur et al., 2011). Together these
data indeed support our ﬁndings that IL-22 induction may be
important during a malaria infection.
IL-22 has been shown to have several important roles. Its
receptor is not present on hematopoietic cells but on tissues, par-
ticularly epithelial cells such as gut epithelial cells, keratinocytes,
and hepatocytes (Wolk and Sabat, 2006), and it has an impor-
tant cyto-protective function contributing to tissue and cell repair
(Sonnenberg et al., 2011). Given our ﬁndings of increased liver
damage in P. chabaudi infection in IL-22 KO mice, its abil-
ity to protect hepatocytes during liver inﬂammation (Radaeva
et al., 2004; Xing et al., 2011; Xu et al., 2011) is of particular
relevance.
IL-22 can be produced by many different types of lympho-
cytes of the innate and adaptive immune system, including CD4+
T cells, CD8+ T cells (Zheng et al., 2007; Nograles et al., 2009),
innate lymphoid cells (Taube et al., 2011), the NK-22 subset of
natural killer cells (Zenewicz et al., 2008; Cella et al., 2009), γδ+
T cells (Martin et al., 2009; Simonian et al., 2010), and CD11c+
DCs (Zheng et al., 2007). Surprisingly in our study, CD8+ T cells
were a signiﬁcant source of both IL-22 and IL-17 among liver
mononuclear cells of infected mice. The CD8+ T cells in this P.
chabaudi infection producing IL-17 or IL-22 are reminiscent of a
recently described human population of CD8+ T cells (Billerbeck
et al., 2010). These TC17 cells are deﬁned by the expression of
CD161 and a pattern of molecules consistent with TH17 differen-
tiation including IL-17 and IL-22 cytokines. In addition,TC17 cells
are markedly enriched in tissue samples, such as liver, and maybe
associated with protection against human Hepatitis C pathology
(Billerbeck et al., 2010), in line with the known hepato-protective
function of IL-22 (Radaeva et al., 2004; Xing et al., 2011; Xu
et al., 2011). In our mouse model of malaria, however, we did
not detect any IL-17/IL-22 double-producing cells. In this respect
the CD8+ T cells secreting either IL-17 or IL-22 may be more
similar to the IL-22-producing CD4+ T cells, which have been
shown to be distinct from TH17, TH1, and TH2 cells (Trifari et al.,
2009).
Induction of IL-22 in vitro depends on IL-6, IL-23, and IL-
1β (Ghoreschi et al., 2010) but unlike IL-17A, is inhibited by
TGF-β (Rutz et al., 2011), although that has not been formally
shown for these IL-22-producing CD8+ T cells. IL-6, TGF-
β, and IL-1-β are all produced during acute malaria in mice
(Artavanis-Tsakonas et al., 2003; Li et al., 2003) and humans
(Walther et al., 2006), and by myeloid cells such as dendritic
cells and inﬂammatory monocytes (Voisine et al., 2010), which
have interacted with or phagocytosed hemozoin, parasite mate-
rial, or iRBC (reviewed in Shio et al., 2010). Furthermore, IL-6
and TGF-β are abundant in damaged or injured livers (Streetz
et al., 2003; Knight et al., 2005), and as liver pathology has been
documented during blood-stage malaria infections (Kochar et al.,
2003; Devarbhavi et al., 2005; Whitten et al., 2011), it seems
likely that the environment in the liver could be conducive to
the differentiation of IL-17- and/or IL-22-producing CD8+ T
cells. Therefore, IL-22-producing CD8 T cells in the liver may
include both; inﬁltrating cells as well as liver-differentiated IL-
17 and IL-22-producing CD8 T cells, although this need to be
determined.
The mechanism of the liver damage that is protected by IL-
22 in this infection is not known. In P. berghei infections of
mice, different cells and molecules have been implicated, includ-
ing NKT, MyD88, IL-12, IFN-γ, and free Heme (Adachi et al.,
2001; Seixas et al., 2009; Findlay et al., 2010), and one study
has shown that liver damage occurs independently of CD8+ T
cells (Haque et al., 2011). Free heme has also been implicated
in liver damage in P. chabaudi infections in a susceptible mouse
strain (Seixas et al., 2009). Whether or not there is an additional
role for other pro-inﬂammatory cytokines in this remains to be
determined.
The signaling pathway by which IL-17 and IL-22 production
are induced in CD8+ T cells in this P. chabaudi infection has
still to be elucidated. As we only evaluated mice lacking IL-22,
it is unclear whether, similarly to CD4+ T cells (Veldhoen et al.,
2008), AHR and Notch signaling are required for IL-22 expression
in the liver CD8+ T cells in this malaria infection, and further
studies are required to delineate whether this pathway is a key
mechanism involved in protection from liver damage during a pri-
mary P. chabaudi infection via the induction of IL-22-producing
CD8+ T cells.
In conclusion, we propose that the IL-22+ CD8+ T cells, which
appear in the liver in this P. chabaudi infection prevent or ame-
liorate potential toxic damage to liver cells. The relevance of these
ﬁndings to human severe malaria remains to be established. As
hepatic dysfunction can be a signiﬁcant feature of human malaria
it would be important to relate our ﬁndings to the IL-22 gene
polymorphisms found to be associated with resistance or suscep-
tibility to P. falciparum malaria, as well as to the magnitude of
IL-22 response in severe and mild disease.
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APPENDIX
Table A1 | Primers used for Real-time quantitative PCR reactions.
Forward sequence Reverse sequence
Ubiquitin TGGCTATTAATTATTCGGTCTGCAT GCAAGTGGCTAGAGTGCAGAGTAA
IL-17A TCCAGAAGGCCCTCAGACTA CAGGATCTCTTGCTGGATG
IL-17F CTGAGGCCCAGTGCAGACA GCTGAATGGCGACGGAGTT
IL-22 TCCGAGGAGTCAGTGCTAAA AGAACTGCTTCCAGGGTGAA
IFN-• GGATGCATTCATGAGTATTG CTTTTCCGCTTCCTGAGG
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